Our look is new. Our purpose is the same. Learn more about our brand evolution.
Our look is new. Our purpose is the same. Learn more about our brand evolution.
Presenter: Seth Friedman, PhD
Join us for an FSHD University webinar exploring the role of MRI in facioscapulohumeral muscular dystrophy (FSHD) clinical trials. Dr. Seth Friedman will discuss how advanced imaging helps track disease progression, select trial participants, and evaluate therapeutic impact. This will provide an opportunity to learn why MRI is becoming a vital biomarker in the quest for effective FSHD treatments.
Seth Friedman Ph.D. is Manager of Innovation Imaging and Simulation Modeling and a PI in the Center for Respiratory Biology and Therapeutics. His team’s collaborative work focuses on finding new ways to quantify imaging biomarkers and better follow disease progression and therapeutic intervention. Current studies are investigating congenital airway narrowing, characterizing abnormal tissue features in tracheomalacia, 3D printing for surgical planning, developing software for epilepsy surgical planning, and understanding the overlap between MRI and molecular features (e.g. RNA) in muscular dystrophy.
